takeaway meet
summari yesterday opportun meet
manag team includ presid incom ceo
geoff martha key takeaway meet includ
mdt key messag innov driven growth expect
acceler growth rate meaning higher level
sustain plan add healthier cadenc
capit alloc decis increas wamgr
compani see posit diabet make
invest fix divis surgic robot submiss
approv launch timelin remain intact pelvic
busi bolster next-gener devic
launch rais price target
assum ep estim
innov acceler growth rate meaning
higher level meet kick manag key
messag focu organ innovation-driven
growth focu plan acceler growth rate
meaning higher level importantli keep sustain
term base recal outlin plan sustain
annual organ revenu growth long term
investor day remain confid pipelin product
across four busi drive meaning higher level
sustain growth come year
remain commit adjust ep growth
near longer term plan period bottom line
remain commit long-rang target adj ep growth
durat plan period laid investor
day look ahead manag plan host next
investor day june detail long rang target
laid abl garner increment color
think bottom line come year
specif aforement meaning higher sustain
growth compani expect go forward come
expens ep growth plan adjust
adj ep growth goal would note mention
past could year cant off-set neg
impact fx ep growth would fall short target
ask impact extra sell week
produc headwind adjust ep growth manag
mention would attempt manag remain
year ie invest upsid offset headwind
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani data secur llc estim reuter
continu previou page
inorgan growth bigger piec stori manag prioriti execut
pipelin incom ceo geoff martha mention increas cadenc inorgan opportun drive
compani wamgr higher time rel past year integr covidien
regard inorgan growth manag continu say continu look tuck-in
supplement top-lin growth specif compani would implement capit alloc model across
busi group process overal believ manag plan
add healthier cadenc come year
note mani posit diabet make invest fix busi
view manag question cgm continu glucos monitor
platform need get better moment play strength pump specif
note grow robustli ou big scale advantag would end even
import given new product flow would reach ou region first next-gen pump minim
close launch phase anticip better time rang approach
seen feasibl studi term featur compani plan focu
system would forgiv user behavior keep patient rang
miss meal bolu plan show use case data extrem condit attd advanc
 treatment diabet meet februari full pivot trial data ada
american diabet associ meet june fda submiss forthcom
previous issu timelin remain track per us/ou launch end april
addit continu make progress next-gener cgm sensor synergi pivot
trial enrol continu progress close wrap per synergi
plan start studi april
remain commit robot assist surgeri ra platform timelin financi
impact remain commit execut ra strategi laid investor
updat hartford ct recent competitor confer compani note softwar
releas could potenti push first human procedur surgic robot howev
import per manag chang state timelin global submiss
launch continu look initi launch april
like india view remain commit submit ce mark may-juli
 may-octob term approv continu expect ce
mark novemb fda clearanc sometim late lastli
reiter expect growth contribut ra platform mitg
gener interstim help close competit gap pelvic late last year
file pre-market approv pma interstim micro recharg sacral neuromodul
snm devic overact bladder oab fecal incontin fi well file surescan
mri lead would allow full-bodi mri condit label current interstim ii interstim
micro week announc receiv ce mark approv europ
interstim micro interstim surescan mri lead becam avail europ januari
note meet first case micro europ schedul next week
think approv support confid approv time spring howev
europ account less world-wide snm market expect product gap
competit disadvantag quarter micro market us
indic us guidanc contempl share loss micro launch
believ mdt commit pursu snm improv technolog catalyz market
benefit long run lastli believ primari cell recharge-fre devic
remain major market approxim go forward benefit offer
option clinician
price target
price target base cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ acceler growth stori trade discount peer organ growth
acceler come quarter due new product launch micra av surgic
robot linq diabet pump next gener interstim renal denerv
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
